Plasma cell leukemia
MONDO:0018689An aggressive plasma cell neoplasm characterized by the presence of neoplastic plasma cells in the peripheral blood. It is characterized by the presence of a circulating clonal plasma cell count that exceeds 2x10^9/L or is 20% of the leukocyte differential count.
Also known as: PCL, leukaemia plasmacytic, leukemia plasmacytic, plasma cell leukemia, plasmacytic leukaemia, plasmacytic leukemia, leukemia, plasma cell
2045 clinical trials for this condition and its sub-types, 32 tagged with Plasma cell leukemia itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New drug cocktail aims to beat myeloma
Disease control Not yet recruitingThis Phase 2 trial tests a new drug called QLS4131, given under the skin, in combination with other medications for people with malignant plasma cell neoplasms like multiple myeloma. The study will compare different drug combinations to see which works best at shrinking tumors an…
Phase 2 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New dual-target CAR-T therapy takes on hard-to-treat blood cancers
Disease control Not yet recruitingThis early-phase study tests a new treatment called CAR19-BCMA CAR-T for people with certain blood cancers (plasma cell neoplasms or lymphomas/leukemias) that have returned or not responded to at least three prior treatments. The therapy uses a patient's own immune cells, modifie…
Early phase 1 • Sponsor: Affiliated Hospital to Academy of Military Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Experimental CAR-T therapy targets tough blood cancers in early trial
Disease control Not yet recruitingThis early-phase trial tests a new type of immune cell therapy called GPRC5D CAR-T in 18 people with relapsed or treatment-resistant plasma cell disorders, such as multiple myeloma. The therapy involves giving patients a single infusion of their own modified immune cells designed…
Early phase 1 • Sponsor: Qi deng • Aim: Disease control
Last updated Jun 27, 2026 08:15 UTC
-
Engineered immune cells take aim at Hard-to-Treat blood cancer
Disease control Not yet recruitingThis early-phase trial tests a personalized treatment called IASO104 for people with relapsed or refractory multiple myeloma, a blood cancer that has not responded to standard therapies. IASO104 is made from a patient's own immune cells, which are genetically modified to recogniz…
Early phase 1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New combo attack on myeloma: antibody first, then CAR-T
Disease control Not yet recruitingThis early-phase trial tests whether giving a bispecific antibody (QLS32015) before CAR-T cell therapy can improve outcomes for 20 adults with relapsed/refractory multiple myeloma. The study measures how many patients respond and tracks side effects. It is a single-arm, open-labe…
Early phase 1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC